Din aceeași categorie

Oncolog-Hematolog.ro

Tratamentul carcinomului renal metastatic cu terapiile TKI şi mTOR: prezentare de caz

Oncolog-Hematolog.ro

De actualitate în cancerul pulmonar

Oncolog-Hematolog.ro

Tratamentul cancerului gastric în spitalele judeţene, între standardul de aur şi practica clinică

When guideline-recommended drugs are not reimbursed by the insurance, the clinicians face significant challenges in treatment decision-making. The main difficulties include:

1. Compromised evidence-based care

• Clinicians may be unable to prescribe the most effective or safest therapy as recommended by national or international guidelines, potentially leading to suboptimal patient outcomes.
• Alternative therapies may be less effective, have a less favorable safety profile, or lack robust supporting evidence.

2. Ethical and professional dilem­mas

• Physicians may experience moral distress when unable to offer the standard of care due to financial barriers.
• There is a tension between advocating for the best patient care and the realities of healthcare system constraints.

3. Equity and access issues

• Patients with greater financial means may access recommended therapies out-of-pocket, while others cannot, leading to disparities in care.
• This can undermine trust in the health­care system and the clinician-patient relationship.

4. Increased administrative burden

• Clinicians and their teams may spend significant time on appeals, prior authorizations, or seeking alternative funding, diverting resources from direct patient care.
• Navigating complex insurance policies and documentation requirements can delay treatment initiation.

5. Patient communication challenges

• Explaining to patients why the optimal therapy is not accessible can be difficult and may cause frustration, anxiety, or loss of confidence in the healthcare team.
• Shared decision-making becomes more complex when financial considerations override clinical priorities.

6. Potential for inferior outcomes

• Use of non-reimbursed, non-guideline therapies may result in lower efficacy, increased toxicity, or higher rates of adverse events.
• There may be a lack of data on the effectiveness of alternative regimens in the specific clinical context.

7. Impact on clinical research and data

• Real-world outcomes may not reflect guideline-based care, complicating the interpretation of observational studies and quality improvement initiatives.

Strategies to address these challenges

• Documentation: clearly document the rationale for guideline-recommended therapy and the impact of insurance denial.
• Appeals and advocacy: engage in the appeals process and advocate for policy changes at institutional or governmental levels.
• Multidisciplinary collaboration: work with pharmacists, case managers and social workers to explore patient assistance programs or alternative funding.
• Patient support: provide counseling and support to help patients navi­gate financial toxicity and understand their options.
• Participation in clinical trials: where available, clinical trials may provide access to otherwise unavailable therapies.

In summary, the lack of reimbursement for guideline-recommended drugs introduces complex clinical, ethical and logistical challenges, often forcing clinicians to balance optimal care with real-world constraints.

The following papers provide relevant evidence and discussion:

1. Green CJ, Maclure M, Fortin PM, Ramsay CR, Aaserud M, Bardal S. Pharmaceutical policies: effects of restrictions on reimbursement. Cochrane Database Syst Rev. 2010;2010(8):CD008654.

The paper shows that implementing restrictions to coverage and reimbursement of selected medications can decrease third-party drug spending, but may adversely affect medication adherence and clinical outcomes.

2. Stone JA, Earl KM, O’Neill BJ, et al. Aligning health care policy with evidence-based medicine: the case for funding direct oral anticoagulants in atrial fibrillation. Can J Cardiol. 2014;30(10):1245-1248.

The paper discusses the misalignment between evidence-based guidelines and reimbursement policy, leading to care gaps and suboptimal outcomes for patients denied access to guideline-based therapies.

3. Lalani HS, Hwang CS, Kesselheim AS, Rome BN. Strategies to Help Patients Navigate High Prescription Drug Costs. JAMA. 2024;332(20):1741-1749.

The paper highlights the structural and policy challenges in the US prescription drug market that impede affordable access to guideline-recommended medications, and the impact on cost-related nonadherence.

4. Wagenschieber E, Blunck D. Impact of reimbursement systems on patient care – a systematic review of systematic reviews. Health Econ Rev. 2024;14(1):22.

The paper shows that economic and financial factors, including reimbursement policies, play a key role in patient treatment decisions and may negatively affect quality of care and patient safety.

5. Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: a major challenge to evidence-based practice. J R Soc Med. 2010;103(5):178-187.

The paper reviews how non-clinical factors, such as reimbursement and insurance coverage, can be significant obstacles to the implementation of evidence-based medicine.

6. Zhang Q, Laporte A. The impact of prescription drug insurance on cost related non-adherence to me­di­ca­tions in Canada: A Heckman sample selection approach. PLoS One. 2023;18(8):e0289776.

The paper examines how the lack of drug insurance coverage increases the risk of cost-related nonadherence, even when guideline-recommended therapies are available.